Literature DB >> 33058229

Programmable C-to-U RNA editing using the human APOBEC3A deaminase.

Xinxin Huang1,2, Junjun Lv1,2, Yongqin Li1,2, Shaoshuai Mao1,2, Zhifang Li3, Zhengyu Jing1,2, Yidi Sun4, Xiaoming Zhang1,2, Shengxi Shen1,2, Xinxin Wang1, Minghui Di1,2, Jianyang Ge1,2, Xingxu Huang1, Erwei Zuo3, Tian Chi1,5.   

Abstract

Programmable RNA cytidine deamination has recently been achieved using a bifunctional editor (RESCUE-S) capable of deaminating both adenine and cysteine. Here, we report the development of "CURE", the first cytidine-specific C-to-U RNA Editor. CURE comprises the cytidine deaminase enzyme APOBEC3A fused to dCas13 and acts in conjunction with unconventional guide RNAs (gRNAs) designed to induce loops at the target sites. Importantly, CURE does not deaminate adenosine, enabling the high-specificity versions of CURE to create fewer missense mutations than RESCUE-S at the off-targets transcriptome-wide. The two editing approaches exhibit overlapping editing motif preferences, with CURE and RESCUE-S being uniquely able to edit UCC and AC motifs, respectively, while they outperform each other at different subsets of the UC targets. Finally, a nuclear-localized version of CURE, but not that of RESCUE-S, can efficiently edit nuclear RNAs. Thus, CURE and RESCUE are distinct in design and complementary in utility.
© 2020 The Authors.

Entities:  

Keywords:  zzm321990RESCUEzzm321990; Apobec; RNA editing; programmable; site-directed RNA editing

Mesh:

Substances:

Year:  2020        PMID: 33058229      PMCID: PMC7667879          DOI: 10.15252/embj.2020104741

Source DB:  PubMed          Journal:  EMBO J        ISSN: 0261-4189            Impact factor:   11.598


  33 in total

Review 1.  Current strategies for Site-Directed RNA Editing using ADARs.

Authors:  Maria Fernanda Montiel-Gonzalez; Juan Felipe Diaz Quiroz; Joshua J C Rosenthal
Journal:  Methods       Date:  2018-11-29       Impact factor: 3.608

2.  Site-directed RNA repair of endogenous Mecp2 RNA in neurons.

Authors:  John R Sinnamon; Susan Y Kim; Glen M Corson; Zhen Song; Hiroyuki Nakai; John P Adelman; Gail Mandel
Journal:  Proc Natl Acad Sci U S A       Date:  2017-10-16       Impact factor: 11.205

Review 3.  The APOBEC Protein Family: United by Structure, Divergent in Function.

Authors:  Jason D Salter; Ryan P Bennett; Harold C Smith
Journal:  Trends Biochem Sci       Date:  2016-06-06       Impact factor: 13.807

4.  Structural Basis for the RNA-Guided Ribonuclease Activity of CRISPR-Cas13d.

Authors:  Cheng Zhang; Silvana Konermann; Nicholas J Brideau; Peter Lotfy; Xuebing Wu; Scott J Novick; Timothy Strutzenberg; Patrick R Griffin; Patrick D Hsu; Dmitry Lyumkis
Journal:  Cell       Date:  2018-09-20       Impact factor: 41.582

5.  The double-domain cytidine deaminase APOBEC3G is a cellular site-specific RNA editing enzyme.

Authors:  Shraddha Sharma; Santosh K Patnaik; Robert T Taggart; Bora E Baysal
Journal:  Sci Rep       Date:  2016-12-15       Impact factor: 4.379

6.  Stem-loop structure preference for site-specific RNA editing by APOBEC3A and APOBEC3G.

Authors:  Shraddha Sharma; Bora E Baysal
Journal:  PeerJ       Date:  2017-12-06       Impact factor: 2.984

7.  Tunable and reversible drug control of protein production via a self-excising degron.

Authors:  Hokyung K Chung; Conor L Jacobs; Yunwen Huo; Jin Yang; Stefanie A Krumm; Richard K Plemper; Roger Y Tsien; Michael Z Lin
Journal:  Nat Chem Biol       Date:  2015-07-27       Impact factor: 15.040

8.  The Ensembl Variant Effect Predictor.

Authors:  William McLaren; Laurent Gil; Sarah E Hunt; Harpreet Singh Riat; Graham R S Ritchie; Anja Thormann; Paul Flicek; Fiona Cunningham
Journal:  Genome Biol       Date:  2016-06-06       Impact factor: 13.583

9.  Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage.

Authors:  Alexis C Komor; Yongjoo B Kim; Michael S Packer; John A Zuris; David R Liu
Journal:  Nature       Date:  2016-04-20       Impact factor: 49.962

10.  Efficient and precise editing of endogenous transcripts with SNAP-tagged ADARs.

Authors:  Paul Vogel; Matin Moschref; Qin Li; Tobias Merkle; Karthika D Selvasaravanan; Jin Billy Li; Thorsten Stafforst
Journal:  Nat Methods       Date:  2018-07-02       Impact factor: 28.547

View more
  6 in total

Review 1.  Cas-Based Systems for RNA Editing in Gene Therapy of Monogenic Diseases: In Vitro and in Vivo Application and Translational Potential.

Authors:  Vasiliy V Reshetnikov; Angelina V Chirinskaite; Julia V Sopova; Roman A Ivanov; Elena I Leonova
Journal:  Front Cell Dev Biol       Date:  2022-06-16

2.  Programmable RNA base editing with a single gRNA-free enzyme.

Authors:  Wenjian Han; Wendi Huang; Tong Wei; Yanwen Ye; Miaowei Mao; Zefeng Wang
Journal:  Nucleic Acids Res       Date:  2022-08-27       Impact factor: 19.160

3.  RNA Editing Therapeutics: Advances, Challenges and Perspectives on Combating Heart Disease.

Authors:  Maria Birgaoanu; Marco Sachse; Aikaterini Gatsiou
Journal:  Cardiovasc Drugs Ther       Date:  2022-10-14       Impact factor: 3.947

Review 4.  Site-directed RNA editing: recent advances and open challenges.

Authors:  Hamid Mansouri Khosravi; Michael F Jantsch
Journal:  RNA Biol       Date:  2021-09-27       Impact factor: 4.652

Review 5.  A Systematic Review of Common and Brain-Disease-Specific RNA Editing Alterations Providing Novel Insights into Neurological and Neurodegenerative Disease Manifestations.

Authors:  Korina Karagianni; Spyros Pettas; Georgia Christoforidou; Eirini Kanata; Nikolaos Bekas; Konstantinos Xanthopoulos; Dimitra Dafou; Theodoros Sklaviadis
Journal:  Biomolecules       Date:  2022-03-17

6.  Is subretinal AAV gene replacement still the only viable treatment option for choroideremia?

Authors:  Ruofan Connie Han; Lewis E Fry; Ariel Kantor; Michelle E McClements; Kanmin Xue; Robert E MacLaren
Journal:  Expert Opin Orphan Drugs       Date:  2021-03-24       Impact factor: 0.694

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.